TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06303414

Intervention type: PROCEDURE
Intervention: Carotid Endarterectomy (CEA)
Description: Carotid endarterectomy (CEA) Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA, although the use of standard or eversion endarterectomy, and a shunt or patch, is left to the discretion of the surgeon.

Intervention type: PROCEDURE
Intervention: Carotid Artery Stenting (CAS)
Description: Carotid artery stenting (CAS) Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 3 days before the CAS procedure and for 90 days after the procedure. They will receive a daily dose of 100 mg aspirin or 75 mg clopidogrel thereafter. For the CAS procedure, general anesthesia and predilation prior to stent placement are recommended. Use of an embolic protection device is advised for all patients who undergo CAS.

Intervention type: PROCEDURE
Intervention: Hybrid Surgery
Description: Hybrid Surgery Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA, CAS and Hybrid Sugery. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 5 days before the hybird surgery procedure. If they had stenting procedure, they will receive a daily dose of 100 mg aspirin and 75 mg clopidogrel thereafter. If not, they will take either 100mg aspirin or 75mg clopidogrel daily for life.
Study: NCT03438188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Quit Attempt
Description: Smokers will be studied under 2 conditions: smoking as usual and during a 4 day practice quit attempt.
Study: NCT03229967

Intervention type: DIAGNOSTIC_TEST
Intervention: 16S rRNA stool microbiome sequencing.
Description: This is an observational cohort that will undergo gut microbiome sequencing.

Intervention type: DIAGNOSTIC_TEST
Intervention: 16S rRNA stool microbiome sequencing.
Description: This is an observational cohort that will undergo gut microbiome sequencing.

Intervention type: DIAGNOSTIC_TEST
Intervention: 16S rRNA stool microbiome sequencing.
Description: This is an observational cohort that will undergo gut microbiome sequencing.
Study: NCT01419938

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light therapy and Cognitive behaviour therapy
Description: Light therapy every morning during 30 minutes for two weeks. CBT for 90 to 120 minutes weekly during four weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light therapy
Description: Light therapy every morning during 30-45 minutes for two weeks.
Study: NCT00912223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplant
Description: NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~The conditioning regimen will consist of the following:~* Rituxan 375 mg/m\^2 on Day -13~* Rituxan 1000 mg/m\^2 on Days -6, +1, and +8~* Fludarabine 30 mg/m\^2 on Days -5 to -3~* Cyclophosphamide 750 mg/m\^2 on Days -5, -4, -3~Day 0 will be the day of the transplant.~The GVHD prophylaxis will consist of the following:~* Tacrolimus .09 mg/kg/po (Day -2 thru Day +180). Doses will be adjusted to maintain blood levels of 5-15 ng/mL.~* Methotrexate 5 mg/m\^2 (Days +1, +3, and +6). Unrelated donor recipients will receive a fourth dose on Day +11.
Study: NCT02196077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI 320/9.6 μg
Description: Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI 160/9.6 μg
Description: Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Study: NCT03193749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone Hydrochloride
Description: Starting (loading) dose 400 mg PO once a day for 10 days. Maintainance dose 200 mg PO once a day for at least 6 months, up to 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Matching placebo for tablets of 200 mg of Amiodarone
Study: NCT01906281

Intervention type: OTHER
Intervention: Blood analyse, arthrocentesis, ultrasound examination

Intervention type: OTHER
Intervention: Blood analyse, arthrocentesis, ultrasound examination
Study: NCT02119806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzodiazepine
Description: Receive as premedication in the Benzodiazepine group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Receive as maintenance in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive as maintenance in the Non-Benzodiazepine group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Receive as maintenance in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive as maintenance in the Non-Benzodiazepine group.
Study: NCT02196077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI 80/9.6 μg
Description: Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD MDI 320 μg
Description: Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF MDI 9.6 μg
Description: Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
Study: NCT02119806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Receive postoperatively in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive postoperatively in the Non-Can receive as premedication in the Non-Benzodiazepine group.
Study: NCT03962322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weaning TDI
Description: Patients will be subjected to a spontaneous breathing test (Cpap 5), that consists in applying a positive end-expiratory pressure of 5 cm H2O for 20 minutes.~A tissue doppler evaluation will then be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration and calculating the speed of muscles displacement and other derived index of muscle function in the modality of ventilation which precedes the trial, during the SBT and after extubation.
Study: NCT04115852

Intervention type: BEHAVIORAL
Intervention: fmri
Description: functional magnetic resonance imaging

Intervention type: BEHAVIORAL
Intervention: fmri
Description: functional magnetic resonance imaging
Study: NCT04690478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic remote blood pressure monitor
Description: Remote blood pressure management group through remote blood pressure management the platform realizes functions such as automatic upload of patient measurement data, intelligent analysis, and early warning reminders

Intervention type: DEVICE
Group type: OTHER
Intervention: Ordinary household electronic sphygmomanometer
Description: One group is distributed a set of ordinary household electronic sphygmomanometer, and the blood pressure is recorded by themselves at home following routine community office follow-up

Intervention type: DEVICE
Group type: OTHER
Intervention: Office electronic sphygmomanometer
Description: One group follows routine community office follow-up and uses office electronic sphygmomanometer to measure blood pressure
Study: NCT01764308

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 1200mg twice a day for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3
Description: 1200mg twice a day for 24 weeks
Study: NCT02219386

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1. Deep dry needling
Description: Deep dry needling and stretch. The intervention included DDN of every active MTrP found in the trapezius muscle using a 4 cm x 0.32 mm acupuncture needle as described by Simons et al. (Simons et al., 1999). Once the needle was inserted into the MTrP previously marked by the blinded assessor, local twitch responses (LTRs) were obtained by using Hong's fast-in and fast-out technique, which involves rapid movements of the needle in and out of the MTrP. After four LTRs, the needle was withdrawn and the area was disinfected with alcohol again (Simons et al., 1999). Then, passive stretch was performed on the trapezius muscle.

Intervention type: OTHER
Group type: OTHER
Intervention: Group 1. Deep dry needling
Description: Deep dry needling and stretch. The intervention included DDN of every active MTrP found in the trapezius muscle using a 4 cm x 0.32 mm acupuncture needle as described by Simons et al. (Simons et al., 1999). Once the needle was inserted into the MTrP previously marked by the blinded assessor, local twitch responses (LTRs) were obtained by using Hong's fast-in and fast-out technique, which involves rapid movements of the needle in and out of the MTrP. After four LTRs, the needle was withdrawn and the area was disinfected with alcohol again (Simons et al., 1999). Then, passive stretch was performed on the trapezius muscle.

Intervention type: OTHER
Group type: OTHER
Intervention: group 2. Passive analitical stretch (performed in both groups)
Study: NCT00028522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R(+)XK469
Description: Given IV
Study: NCT02007278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vildagliptin and metformin (combination)
Description: vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study: NCT02826252

Intervention type: DRUG
Intervention: Iloprost,(Ventavis, BAYQ6256)
Description: Ventavis (Iloprost) nebulizer solution for inhalation as 10 μg/mL (V10) and 20 μg/mL (V20).

Intervention type: DEVICE
Intervention: I-Neb AAD system
Description: Nebulizer, allows digital recording of inhalation data such as doses, inhalations per day and duration of inhalation (per day) etc.
Study: NCT03474094

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery
Description: W1,W2, W3, W4 \& W5: RADIOTHERAPY. A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6 and W9: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W11: SURGERY. Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent
Study: NCT01764308

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 tablets twice a day for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 tablets twice a day for 24 weeks
Study: NCT03474094

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 2 cycles of atezolizumab followed by surgery then post-operative radiotherapy
Description: W1 and W4: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W7, W8, W9, W10 \& W11: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.
Study: NCT03360110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phoebe test lens
Description: Daily disposable contact lens
Study: NCT03474094

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.
Description: W1,W2, W3, W4 \& W5: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W11 and W14: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval
Study: NCT01163006

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Polydextrose and soluble gluco fibre
Description: Polydextrose and soluble gluco fibre

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Polydextrose and soluble gluco fibre
Description: Polydextrose and soluble gluco fibre

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polydextrose and soluble gluco fibre
Description: Polydextrose and soluble gluco fibre

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polydextrose and soluble gluco fibre
Description: Polydextrose and soluble gluco fibre
Study: NCT00502853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1000mg iv on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10-25mg/week
Study: NCT01361867

Intervention type: DEVICE
Group type: OTHER
Intervention: Robot-induced perturbations
Description: A robotic system is used to generate mechanical perturbations and study how subjects generate motor adaptations in response to the mechanical perturbations.
Study: NCT02407587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cochlear implants
Description: PET scans for the mature patients with unilateral cochlear implants and preserved hearing~4 states and each state will be repeated 3 times Cochlear implant only Residual hearing only Combination of implant and residual hearing No auditory stimulation
Study: NCT03609190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: i.v. infusion of 0.25 mg/kg S-ketamine over 40 min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: i.v. infusion of NaCl over 40 min
Study: NCT01472978

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: metronidazole
Description: Metronidazole, 500 mg three times a for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Description: Metronidazole, 500 mg three times a for 10 days
Study: NCT01687855

Intervention type: DEVICE
Intervention: Ultrafast Magnetic Resonance Imaging
Description: MRI was performed with a 1.5 superconducting magnet (Gyroscan Intera type, Philips Co. Holland) in a posterior and anterior neck coil. The sequence used to perform the ultrafast MRI was a fast gradient- echo plus sequence. Technical parameters included: echo time, 12 msec; repetition time, 2.3 msec; flap angle, 250; matrix, 192 × 512; section thickness, 7 mm. The imaging time per slice for this sequence was 0.92 sec. A total of 120 consecutive images were obtained as a single section, with a total imaging time of 110.4 seconds. MRI scanning was carried out with the subject first asleep, then whilst awake after 20 minutes in quiet respiration. All images were inputted to the PACS workstation.

Intervention type: DEVICE
Intervention: Ultrafast Magnetic Resonance Imaging
Description: MRI was performed with a 1.5 superconducting magnet (Gyroscan Intera type, Philips Co. Holland) in a posterior and anterior neck coil. The sequence used to perform the ultrafast MRI was a fast gradient- echo plus sequence. Technical parameters included: echo time, 12 msec; repetition time, 2.3 msec; flap angle, 250; matrix, 192 × 512; section thickness, 7 mm. The imaging time per slice for this sequence was 0.92 sec. A total of 120 consecutive images were obtained as a single section, with a total imaging time of 110.4 seconds. MRI scanning was carried out with the subject first asleep, then whilst awake after 20 minutes in quiet respiration. All images were inputted to the PACS workstation.
Study: NCT02570230

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NSS
Description: NSS infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine 0.2 mg/kg/hr intravenous infusion
Study: NCT03836456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Resilience Training
Description: Mindfulness is a form of cognitive training that cultivates self-regulative ability and enhances resilience

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program
Description: This is a validated active control developed to serve as a control for mindfulness-based studies.
Study: NCT02408952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Physician
Description: The screening, brief intervention and referral to treatment is delivered by the Primary Care Physician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Medicine Specialist
Description: The screening, brief intervention and referral to treatment is delivered by the Behavioral Medicine Specialist.
Study: NCT04262960

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: active CPAP
Description: auto-PAP with pressure between 4 and 20 cm H2O will be administered to randomized patients

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Device: sham-CPAP
Description: The sham-CPAP will be fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al, with pressure that no greater than 1cm H2O.
Study: NCT02085226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creative Engagement Intervention
Description: The CEI has 5 component stages which map the participant's journey with the Artist~1. Meeting with Artist, discuss interests, stroke and explore initial creative goals.~2. Introduction to materials and mark making to create interpretations of established images.~3. From mark making and interpretations to developing personal project ideas.~4. Turning personal project ideas into creative finished pieces.~5. Review of completed work, mounting and display of work, future plans.~It is recognised that participants will progress differently. Components may be repeated or retuned to or may be addressed simultaneously. Participants may progress rapidly and so move from stage 5 back to stages 2, 3 or 4 to progress new work or experience new materials or processes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Portfolio Group
Description: The Portfolio group will receive conventional rehabilitation activity at each site. In addition, to control for effects of art related attention received by the intervention group, after baseline assessment and randomisation, this group will receive from the research assistant, a portfolio of work produced by previous participants of the Tayside CEI, with details of community programmes that people with stroke can attend after hospital discharge. Participants will be invited to view the portfolio during their stay. Prior to outcome assessment, the research assistant will visit participants again to answer questions and to discuss options for community programmes, if the person is interested.
Study: NCT03340298

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fiber
Description: the intervention of different sources of dietary fibers

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fiber
Description: the intervention of different sources of dietary fibers

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fiber
Description: the intervention of different sources of dietary fibers
Study: NCT04549623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel end-tidal CO2 monitoring device
Description: Apart from SpO2 and respiratory motion monitoring, the EtCO2 monitoring device is used to detect CO2 from nose and mouth simultaneously.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpO2 and respiratory motion monitoring
Description: Finger SpO2 and ECG-based respiratory motion monitoring are used during operation.
Study: NCT00868751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Initial therapy: Tocilizumab dosed by body weight (8mg/kg based on body weight ≥ 30kg) given by intravenous infusion every two weeks for 12 weeks.~Extension of therapy: Continuation of treatment with tocilizumab at 8mg/kg by body weight given by intravenous infusion every 2 weeks based upon achievement of Primary Objective by week 12, OR continuation of treatment with escalation of tocilizumab dose to 12mg/kg by body weight, given by intravenous infusion every two weeks, for failure to achieve ACR JIA30 at 12 weeks or ACR JIA50 response at any time after week 16.
Study: NCT03510078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin for glycemic control according to the allocation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin for glycemic control according to the allocation
Study: NCT02770768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flibanserin
Description: Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
Study: NCT00825981

Intervention type: OTHER
Intervention: screening coagulation abnormalities
Description: if specific coagulation abnormalities are observed which increase patient's risk of bleeding, appropriate treatment will start
Study: NCT01158014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fibrin Glue, Quixil
Description: quixil 0.1 ml

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: vicryl 10/0